Journal Scans
Trastuzumab-Induced Cardiotoxicity: Clinical and Prognostic Implications of Troponin I Evaluation
Troponin I Identifies Cardiotoxicity Risk With Trastzumab
D Cardinale, A Colombo, R Torrisi, MT Sandri, M Civelli, M Salvatici, G Lamantia, N Colombo, S Cortinovis, MA Dessanai, F Nolè, F Veglia, CM Cipolla
20100702
2010 Aug 2
J Clin Oncol
Trastuzumab-Induced Cardiotoxicity: Clinical and Prognostic Implications of Troponin I Evaluation
J Clin Oncol. 2010 Aug 2;[Epub Ahead of Print], D Cardinale, A Colombo, R Torrisi, MT Sandri, M Civelli, M Salvatici, G Lamantia, N Colombo, S Cortinovis, MA Dessanai, F Nolè, F Veglia, CM Cipolla
TAKE-HOME MESSAGE
Abstract
SUMMARY
OncologySTAT Editorial Team
Trastuzumab targets human epidermal growth factor receptor 2 (HER2), which is overexpressed in up to 30% of all breast cancers. However, cardiotoxicity, mainly asymptomatic left ventricular ejection fraction (LVEF) reduction or overt heart failure (HF), occurs in up to 34% of patients treated with trastuzumab, particularly when it is used with anthracyclines. Anthracyclines may also cause cardiotoxicity, but the pathologic changes and outcomes differ from those caused by trastuzumab. Unlike anthracycline-induced...
